Guizhou Bailing Group Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Guizhou Bailing Group Pharmaceutical's earnings have been declining at an average annual rate of -50.4%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 8.1% per year.
Key information
-50.4%
Earnings growth rate
-50.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 8.1% |
| Return on equity | -13.0% |
| Net Margin | -10.1% |
| Next Earnings Update | 28 Aug 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Guizhou Bailing Group Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 4,504 | -455 | 2,898 | 29 |
| 31 Dec 23 | 4,263 | -415 | 2,630 | 42 |
| 30 Sep 23 | 4,251 | 179 | 2,028 | 32 |
| 30 Jun 23 | 4,157 | 175 | 2,069 | 33 |
| 31 Mar 23 | 3,893 | 166 | 1,985 | 35 |
| 01 Jan 23 | 3,540 | 138 | 1,808 | 22 |
| 30 Sep 22 | 3,232 | 98 | 1,687 | 20 |
| 30 Jun 22 | 3,121 | 120 | 1,524 | 28 |
| 31 Mar 22 | 3,097 | 121 | 1,532 | 23 |
| 01 Jan 22 | 3,111 | 118 | 1,547 | 30 |
| 30 Sep 21 | 3,050 | 112 | 1,477 | 49 |
| 30 Jun 21 | 3,081 | 125 | 1,485 | 42 |
| 31 Mar 21 | 3,064 | 130 | 1,478 | 43 |
| 31 Dec 20 | 3,088 | 152 | 1,456 | 37 |
| 30 Sep 20 | 2,760 | 142 | 1,323 | 18 |
| 30 Jun 20 | 2,777 | 178 | 1,280 | 22 |
| 31 Mar 20 | 2,923 | 210 | 1,266 | 29 |
| 31 Dec 19 | 2,851 | 283 | 1,198 | 25 |
| 30 Sep 19 | 3,243 | 482 | 1,248 | 22 |
| 30 Jun 19 | 3,174 | 514 | 1,146 | 31 |
| 31 Mar 19 | 3,161 | 571 | 1,179 | 32 |
| 31 Dec 18 | 3,137 | 563 | 1,137 | 31 |
| 30 Sep 18 | 2,844 | 562 | 1,006 | 43 |
| 30 Jun 18 | 2,679 | 550 | 975 | 49 |
| 31 Mar 18 | 2,663 | 537 | 942 | 37 |
| 31 Dec 17 | 2,592 | 526 | 955 | 37 |
| 30 Sep 17 | 2,435 | 515 | 903 | 22 |
| 30 Jun 17 | 2,420 | 505 | 905 | 0 |
| 31 Mar 17 | 2,398 | 507 | 884 | 0 |
| 31 Dec 16 | 2,214 | 482 | 801 | 0 |
| 30 Sep 16 | 2,185 | 494 | 721 | 0 |
| 30 Jun 16 | 2,109 | 448 | 712 | 0 |
| 31 Mar 16 | 1,944 | 430 | 641 | 0 |
| 31 Dec 15 | 1,899 | 411 | 622 | 0 |
| 30 Sep 15 | 1,804 | 367 | 616 | 0 |
| 30 Jun 15 | 1,699 | 358 | 570 | 0 |
| 31 Mar 15 | 1,606 | 329 | 538 | 0 |
| 31 Dec 14 | 1,575 | 310 | 530 | 0 |
| 30 Sep 14 | 1,521 | 289 | 520 | 0 |
| 30 Jun 14 | 1,460 | 284 | 476 | 0 |
| 31 Mar 14 | 1,418 | 279 | 461 | 0 |
| 31 Dec 13 | 1,405 | 270 | 467 | 0 |
| 30 Sep 13 | 1,431 | 239 | 480 | 0 |
| 30 Jun 13 | 1,444 | 245 | 456 | 0 |
Quality Earnings: 002424 is currently unprofitable.
Growing Profit Margin: 002424 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002424 is unprofitable, and losses have increased over the past 5 years at a rate of 50.4% per year.
Accelerating Growth: Unable to compare 002424's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 002424 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).
Return on Equity
High ROE: 002424 has a negative Return on Equity (-12.97%), as it is currently unprofitable.